Takeda's Interest Likely To Flush Out Further Shire Suitors
As Takeda discloses that it is considering making a bid to acquire Shire, other big pharma companies look likely to assess their own interest in the firm. Pfizer and AbbVie are among those that may lay their cards on the table.
You may also be interested in...
Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing.
Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets.
Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.